Compare GE Aerospace (GE) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs Twist Bioscience Corp — how do they compare? GE Aerospace trades at $305.24 (market cap $317.10B), while Twist Bioscience Corp trades at $159.89 (market cap $10.08B). The key difference: GE Aerospace is far larger — about 31.5× Twist Bioscience Corp's market cap, and GE Aerospace pays a 0.62% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Aerospace for 111 Days and Twist Bioscience Corp for 27 Days on average.
| GE | TWST | |
|---|---|---|
Market Cap | $317.10B | $10.08B |
Volume | 6,320,106 | 4,229,037 |
Sector | Industrials | Health |
52-Week High | $381.22 | $205.00 |
52-Week Low | $273.25 | $25.45 |
Typical Hold Time | 111 Days | 27 Days |
Enterprise Value | $326.91B | $10.01B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Aerospace trades at $303.62, down 1.86% amid broader market weakness, with technical indicators showing bearish momentum despite strong fundamentals. The company has consistently beaten earnings expectations with Q2 2026 EPS of $2.02 exceeding estimates, while revenue growth accelerated to $45.86 billion in 2025. Recent news highlights GE's $12 billion acquisition of Consolidated Precision Products to address supply chain constraints in jet engine components.
The stock presents a compelling value opportunity with a 35% upside to the consensus price target of $409.60, supported by 24 buy ratings and no sell recommendations. However, high valuation multiples and integration risks from the CPP acquisition warrant caution. Strong free cash flow generation and shareholder returns through dividends and buybacks provide downside protection.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
